CAP: Doxazosin in the Treatment of Co-Occurring PTSD and Alcohol Use Disorders

Phase 2 Completed 144 enrolled VA Office of Research and Development Medical University of South Carolina · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The proposed study will examine the efficacy of doxazosin in the treatment of PTSD and alcohol use disorder or substance use disorders.

Timeline

Start: 2016-06-01
Primary completion: 2019-12-16
Completion: 2019-12-16

Outcome

Missed primary endpoint

paper but, contrary to hypotheses, no significant differences were observed between groups. PMID 36883885 ↗

paper Doxazosin was safe and tolerable but was not more effective than placebo in reducing PTSD or AUD severity in this dually diagnosed sample. PMID 36883885 ↗

Publications

Back SE, Flanagan JC, Mintz J, Brady KT, Jones J, Jarnecke AM, Joseph JE, Shirley DW, Malcolm RJ, Hamner M, Litz BT, Niles BL, Young-McCaughan S, Keane TM, Peterson AL. A Double-Blind Randomized Controlled Trial of Doxazosin for Co-Occurring PTSD and Alcohol Use Disorder in Veterans. J Clin Psychiatry. 2023 Mar 8;84(2):21m14367. doi: 10.4088/JCP.21m14367.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Doxazosin	Unknown	16 mg	—